Ron Squarer
Chairman at ADC THERAPEUTICS SA
Net worth: 7 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Flynn | M | 70 |
Deciphera Pharmaceuticals LLC
 Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 21 years |
| Steven Hoerter | M | 53 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 6 years |
| James Bristol | M | 77 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 17 years |
| John Orwin | M | 62 | 12 years | |
| Chris Cline | M | 40 | 10 years | |
| Dennis Walsh | M | 56 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 years |
| Victor Sandor | M | 57 | 10 years | |
| Ameet Mallik | M | 51 | 2 years | |
| Susan Kelley | M | 69 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 years |
| John Martin | M | 63 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 9 years |
| Franklin Friedman | M | 66 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 5 years |
| Patricia Allen | F | 62 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | 8 years |
| Douglas Giordano | M | 61 | 5 years | |
| Jeffrey Meckler | M | 57 | 10 years | |
| Eric Dube | M | 51 | 5 years | |
| Gary Lyons | M | 73 | 10 years | |
| Edward Benz | M | 78 | 5 years | |
| Bryan Supran | M | - | 5 years | |
| Sandra Calvin | F | 59 | 10 years | |
| Tim Coughlin | M | 57 | 9 years | |
| Sandra E. Poole | F | 60 | 5 years | |
| Elizabeth Reed | F | 53 | 7 years | |
| Kimberly Pope | F | 57 | 8 years | |
| Jama Pitman | M | 45 | 9 years | |
| Suzanne Bruhn | M | 60 | 4 years | |
| Thomas Pfisterer | M | 42 | 8 years | |
| Ruth Williams-Brinkley | F | 72 | 3 years | |
| Tyrell J. Rivers | M | 51 | 6 years | |
| Viviane Monges | F | 60 | 3 years | |
| Margaret M. Madden | F | - | 5 years | |
| Tucker Kelly | M | 53 | 9 years | |
| Peter Hug | M | 65 | 5 years | |
| Roy Baynes | M | 69 | 8 years | |
| Rajesh Devraj | M | - | 13 years | |
| Peter J. Graham | M | 57 | 2 years | |
| Kristen Harrington-Smith | F | 51 | 2 years | |
| Jula Inrig | M | 49 | 2 years | |
| Rodrigo Ruiz Soto | M | - | 7 years | |
| Angela Giannantonio | F | - | - | |
| Kelley Dealhoy | F | - | 2 years | |
| Mohamed Zaki | M | 59 | 1 years | |
| Charlotte Smith | F | - | - | |
| Nivi Nehra | F | - | - | |
| Lisa Amaya Price | F | - | 2 years | |
| Patrick van Berkel | M | 55 | 12 years | |
| Peter Heerma | M | 53 | 5 years | |
| Dashyant Dhanak | M | 63 | 1 years | |
| Robert Azelby | M | 56 | 1 years | |
| Jose Carmona | M | 51 | 2 years | |
| Naomi Eichenbaum | F | - | - | |
| Casey Logan | M | 52 | 6 years | |
| Daniel Martin | M | 49 | 6 years | |
| Jeff Held | M | 55 | 6 years | |
| Jean Bizzari | M | 69 | 2 years | |
| Michael Mulkerrin | M | 69 | 2 years | |
| Bill Rote | M | 61 | 7 years | |
| Matthew Sherman | M | 68 | 5 years | |
| Kevin Brodbeck | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Stephen Aselage | M | 73 | 10 years | |
| Michael Forer | M | 58 | 12 years | |
| Kevin Koch | M | 63 | 15 years | |
| David L. Snitman | M | 72 | 17 years | |
| Christopher Martin | M | 65 | 12 years | |
| Kyle A. Lefkoff | M | 64 | 21 years | |
| Christopher Begley | M | 71 | 8 years | |
| Andrew Robbins | M | 48 | 12 years | |
| Michael Taylor | M | 69 | 7 years | |
| R. Carruthers | M | 66 | 17 years | |
| Tamara Joseph | F | 61 |
Mayne Pharma Ltd.
 Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | 2 years |
| Gwen A. Fyfe | M | 72 | 7 years | |
| F. Ball | M | 68 | 4 years | |
| Heino von Prondzynski | M | 73 | 6 years | |
| Liam Ratcliffe | M | 60 | 2 years | |
| Tricia Haugeto | F | - | - | |
| Charles Baum | M | 65 | 5 years | |
| Curtis Oltmans | M | 60 | 2 years | |
| Andrea N. Flynn | M | - | 1 years | |
| Jason Haddock | M | 54 | 3 years | |
| Thomas G. Moore | M | 72 | 10 years | |
| Charmion Gillmore | F | - |
Mayne Pharma Ltd.
Mayne Pharma Ltd. Pharmaceuticals: OtherHealth Technology Mayne Pharma Ltd. manufactures pharmaceutical products. It distributes generic injectables for the oncology market. The company's competitors include Sandoz, Bedford Labs, and Ebewe. It was founded in November 2005 and is headquartered in Melbourne, Australia. | - |
| Shalini Sharp | F | 49 | 2 years | |
| Laura Clague | F | 64 | 8 years | |
| John L. Zabriskie | M | 85 | 12 years | |
| John Kozarich | M | 74 | 5 years | |
| John Moore | M | 59 | 15 years | |
| Gil van Lunsen | M | 81 | 17 years | |
| David J. Horin | M | 56 | 1 years | |
| Barbara Landers Bowles | F | 76 | 7 years | |
| Sumant Ramachandra | M | 55 | 7 years | |
| Ken Meyers | M | 62 | 7 years | |
| William Dempsey | M | 73 | 4 years | |
| Francis J. Bullock | M | 87 | 14 years | |
| Terrence Kearney | M | 69 | 7 years | |
| Jacques Theurillat | M | 65 | 8 years | |
| Stephen Evans-Freke | M | 72 | 12 years | |
| Dominique Graz | M | 63 | 2 years | |
| Patrick Spine | M | 61 | 2 years | |
| Patricia Henahan | F | - | - | |
| Seema Kumbhat | M | 49 | 5 years | |
| Evert Schimmelpennink | M | 52 | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 80 | 80.00% |
| Switzerland | 20 | 20.00% |
| Australia | 2 | 2.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ron Squarer
- Personal Network
